Breast Cancer-Associated Venous Thromboembolism: Risk Factors, Mechanisms, and Clinical Management
Cancers · 05.05.2026 · 18 (9) · 1486
DOI: 10.3390/cancers18091486 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 05.05.2026. Verfasst von Panlin Xie und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Internal Medicine, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Sch…. Die Arbeit nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Clinical Research Special Project of the Provincial Health Commission, Provincial Health Commission.
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
Venous thromboembolism (VTE) is a clinically significant complication in patients with breast cancer (BC) and may disrupt treatment continuity while contributing to adverse outcomes. Although BC is generally regarded as a relatively low-risk malignancy for VTE compared with several other cancer types, its high incidence and the increasing use of multimodal therapies have resulted in a growing clinical burden of breast cancer-associated VTE. This review summarizes the epidemiological features, risk factors, biological mechanisms, and advances in the prevention and management of breast cancer-associated VTE. Current evidence indicates that patients with cancer have an approximately 4- to 7-fold higher risk of VTE than the general population, with the risk in BC being particularly pronounced during the first 3–6 months after diagnosis. Older age, metabolic comorbidities, advanced disease, and exposure to multiple anticancer therapies have all been associated with an increased risk of VTE. Mechanistically, tissue factor, procoagulant extracellular vesicles, neutrophil extracellular traps, and inflammatory signaling pathways may contribute to breast cancer-associated VTE by promoting coagulation activation and endothelial dysfunction, while also linking thrombosis to immune evasion and Smetastatic progression. Improved identification of high-risk patients, optimization of dynamic risk assessment, and the implementation of individualized prophylactic and anticoagulant strategies may help improve outcomes in patients with BC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of General Internal Medicine, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of Ch…
- Department of Breast Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu 610000, China.
- Department of Plastic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu 610000, China.
- Department of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu 610000, China.
Förderung
- Clinical Research Special Project of the Provincial Health Commission
- Provincial Health Commission
Zitieren
APA
Xie, P., Luo, Y., Hou, L., Xu, J., & Yi, Q. (2026). Breast Cancer-Associated Venous Thromboembolism: Risk Factors, Mechanisms, and Clinical Management. Cancers, 18(9), 1486. https://doi.org/10.3390/cancers18091486
Vancouver
Xie P, Luo Y, Hou L, Xu J, Yi Q. Breast Cancer-Associated Venous Thromboembolism: Risk Factors, Mechanisms, and Clinical Management. Cancers. 2026;18(9):1486. doi:10.3390/cancers18091486
BibTeX
@article{Xie2026,
author = {Xie, Panlin and Luo, Yunbo and Hou, Lingmi and Xu, Jia and Yi, Qun},
title = {Breast Cancer-Associated Venous Thromboembolism: Risk Factors, Mechanisms, and Clinical Management},
journal = {Cancers},
year = {2026},
volume = {18},
number = {9},
pages = {1486},
doi = {10.3390/cancers18091486}
}
EUVIMED